Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Jul 22;16(7):e65127.
doi: 10.7759/cureus.65127. eCollection 2024 Jul.

Prescribing Complexities: A Patient Story Related to Seizure History and the Changing Therapeutic Landscape of Alzheimer's Disease

Mfon E Umoh  1 , Samuel W Terman  2
Affiliations
Case Reports

Prescribing Complexities: A Patient Story Related to Seizure History and the Changing Therapeutic Landscape of Alzheimer's Disease

Mfon E Umoh et al. Cureus. .

Abstract

The therapeutic landscape of Alzheimer's disease (AD) is rapidly changing. Disease-modifying medications for AD that target amyloid-beta (Aß) deposits in the brain have been approved by the Food and Drug Administration (FDA) in recent years. However, there remain many questions about which patients are most appropriate for these medications. One group in particular with unique considerations includes older adults with a prior history of seizures. AD and seizures represent an important, bidirectional relationship. This case report presents a patient story that highlights the importance of discussions around seizure history in consideration of anti-amyloid medications and the importance of risk-benefit assessments when considering anti-amyloid therapeutics for patients with AD.

Keywords: alzheimer’s disease; antiseizure medication; medications; risk-benefit considerations; seizures.

PubMed Disclaimer

Conflict of interest statement

Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: Samuel W Terman declare(s) Unrelated activities- receives salary support from Xenon Pharmaceuticals as a site primary investigator from Xenon Pharmaceuticals. ST also receives support from Xenon Pharmaceuticals for unrelated activities. Samuel W Terman declare(s) a grant from American Epilepsy Society Research and Training Fellowship. ST is funded through the American Epilepsy Society Research and Training Fellowship for Clinicians. The funding sources had no role in the views expressed. Samuel W Terman declare(s) personal fees from Jazz Pharmaceuticals. ST consulted for Jazz Pharmaceuticals for unrelated activities. Mfon Umoh declare(s) a grant from National Institute on Aging. MU is supported on the Health Services and Outcomes Research for Aging Populations Training Program funded by the National Institute on Aging (grant number:T32AG066576). The funding sources had no role in the views expressed. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Similar articles

See all similar articles

References

    1. Two randomized phase 3 studies of aducanumab in early Alzheimer's disease. Budd Haeberlein S, Aisen PS, Barkhof F, et al. J Prev Alzheimers Dis. 2022;9:197–210. - PubMed
    1. Lecanemab in early Alzheimer's disease. van Dyck CH, Swanson CJ, Aisen P, et al. N Engl J Med. 2023;388:9–21. - PubMed
    1. Lecanemab: appropriate use recommendations. Cummings J, Apostolova L, Rabinovici GD, et al. J Prev Alzheimers Dis. 2023;10:362–377. - PMC - PubMed
    1. Aducanumab: appropriate use recommendations. Cummings J, Aisen P, Apostolova LG, Atri A, Salloway S, Weiner M. J Prev Alzheimers Dis. 2021;8:398–410. - PMC - PubMed
    1. Risk factors in developing amyloid related imaging abnormalities (ARIA) and clinical implications. Doran SJ, Sawyer RP. Front Neurosci. 2024;18:1326784. - PMC - PubMed

Publication types

LinkOut - more resources